Federal Register / Vol. 86, No. 178 / Friday, September 17, 2021 / Notices 51893 

the training and the driver’s response to 

feedback from the actigraph. 

Specifically, there are two intervention 

groups: (1) Training plus actigraph 

fatigue level feedback and (2) training 

only with wearing actigraph but no 

fatigue level feedback. The control 

group will receive neither training nor 

feedback on fatigue levels from their 

actigraph. Participants will complete a 

baseline and follow-up Work and Health 

survey, sleep and activities diaries, and 

sleep health knowledge questions 

during each of 5 observation periods. 

The Work and Health survey 

administered in the first observation 

period will be more comprehensive and 

the abbreviated follow up Work and 

Health surveys administered for the 

remaining observation periods will 

serve to capture only responses to 

questions that can change from one 

observation period to the next. Only 

participants randomly selected to take 

the training will complete a training 

evaluation survey used to strengthen the 

training’s effectiveness. Data will also be 

collected from company installed invehicle monitoring systems on safety 

critical events (e.g., hard braking, 

speeding) already collected on all 

drivers as a direct measurement of 

fatigue-related driving performance 

events used to validate self-report data. 

As part of their daily sleep and health 

diaries drivers will be asked to complete 

three-minute psychomotor vigilance 

tests (PVTs) five times throughout the 

day, to directly measure alertness using 

an app installed on an electronic device. 

At the end of the data collection period 

the training will be offered to the 

remaining study participants who will 

be provided an opportunity, but no 

remuneration, to complete the training 

and training survey. 

Study staff will use the findings from 

this evaluation to improve the training 

program, including content and 

delivery, as well as compare fatigue 

between intervention groups. Potential 

impacts of this project include 

improvements in work behaviors for 

coping with shift work and long work 

hours and an objective reduction in 

fatigue compared to the control groups. 

This project is poised to have 

considerable impact in the contribution 

of an evidence base for effective 

interventions that could be used by 

other taxi companies and drivers for 

ride sourcing companies to promote 

strategies in road safety. 

The burden table lists that 120 of the 

180 taxi drivers in the study will 

complete the online training and 

evaluation (approximately three hours). 

All drivers (180) will complete the Work 

and Health survey, and the knowledge 

survey each week of the study (five 

times each per participant). Each 

participant will complete the sleep and 

activity diary five times a day, each day 

for 35 days (175 times total) which will 

require approximately two minutes for 

each response. There will also be three 

meetings for recruitment and enrollment 

(once), fitting the actigraph (weekly), 

and a final meeting (weekly). The total 

estimated annualized burden is 

anticipated to be 2,700 hours. There are 

no costs to participants other than their 

time. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

(in hours) 

Taxi Drivers ....................................... Online Training & Evaluation ........... 120 1 3 360 

Sleep & Activities Diary .................... 180 175 2/60 1,050 

Work & Health Survey ..................... 180 5 45/60 675 

Knowledge survey ............................ 180 5 15/60 225 

Recruitment & Informed Consent .... 180 1 30/60 90 

Initial Meeting (Fit Actigraph) ........... 180 5 10/60 150 

10-minute meeting (turn in devices, 

turn in diary, receive remuneration).

180 5 10/60 150 

Total ........................................... ........................................................... ........................ ........................ ........................ 2,700 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2021–20155 Filed 9–16–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, CDC, pursuant to 

Public Law 92–463. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)– 

RFA–OH–20–002, Commercial Fishing 

Occupational Safety Research 

Cooperative Agreement; and RFA–OH– 

20–003, Commercial Fishing 

Occupational Safety Training Project 

Grants. 

Date: November 03, 2021. 

Time: 1:00 p.m.–3:00 p.m., EDT. 

Place: Video-Assisted Meeting. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: Dan 

Hartley, Ed.D., Scientific Review 

Officer, Office of Extramural Programs, 

National Institute for Occupational 

Safety and Health, CDC, 1095 

Willowdale Road, Morgantown, West 

Virginia 26505, Telephone: (304) 285– 

5812; Email: DHartley@cdc.gov. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

51894 Federal Register / Vol. 86, No. 178 / Friday, September 17, 2021 / Notices 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2021–20152 Filed 9–16–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Clinical Laboratory Improvement 

Advisory Committee (CLIAC) 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

CDC announces the following meeting 

for the Clinical Laboratory Improvement 

Advisory Committee (CLIAC). This 

meeting is open to the public, limited 

only by the webcast lines available. 

Check the CLIAC website on the day of 

the meeting for the web conference link 

www.cdc.gov/cliac. 

DATES: The meeting will be held on 

November 3, 2021, from 11:00 a.m. to 

6:00 p.m., EDT, and November 4, 2021, 

from 11:00 a.m. to 6:00 p.m., EDT. 

ADDRESSES: This is a virtual meeting. 

Meeting times are tentative and subject 

to change. The confirmed meeting 

times, agenda items, and meeting 

materials including instructions for 

accessing the live meeting broadcast 

will be available on the CLIAC website 

at www.cdc.gov/cliac. 

FOR FURTHER INFORMATION CONTACT: 

Nancy Anderson, MMSc, MT(ASCP), 

Senior Advisor for Clinical Laboratories, 

Division of Laboratory Systems, Center 

for Surveillance, Epidemiology and 

Laboratory Services, Office of Public 

Health Scientific Services, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, Mailstop V24–3, 

Atlanta, Georgia 30329–4027, 

Telephone: (404) 498–2741; 

NAnderson@cdc.gov. 

SUPPLEMENTARY INFORMATION:

Purpose: This Committee is charged 

with providing scientific and technical 

advice and guidance to the Secretary, 

HHS; the Assistant Secretary for Health; 

the Director, CDC; the Commissioner, 

Food and Drug Administration (FDA); 

and the Administrator, Centers for 

Medicare and Medicaid Services (CMS). 

The advice and guidance pertain to 

general issues related to improvement in 

clinical laboratory quality and 

laboratory medicine practice and 

specific questions related to possible 

revision of the Clinical Laboratory 

Improvement Amendments of 

1988(CLIA) standards. Examples 

include providing guidance on studies 

designed to improve safety, 

effectiveness, efficiency, timeliness, 

equity, and patient-centeredness of 

laboratory services; revisions to the 

standards under which clinical 

laboratories are regulated; the impact of 

proposed revisions to the standards on 

medical and laboratory practice; and the 

modification of the standards and 

provision of non-regulatory guidelines 

to accommodate technological 

advances, such as new test methods, the 

electronic transmission of laboratory 

information, and mechanisms to 

improve the integration of public health 

and clinical laboratory practices. 

Matters To Be Considered: The agenda 

will include agency updates from CDC, 

CMS, and FDA. In addition to the 

general updates, agency presentations 

will include an overview of the FDA’s 

Center for Biologics Evaluation and 

Research, a laboratory safety update, 

and a status report on the new CLIA 

regulations assessment workgroup. 

Presentations and CLIAC discussion 

will focus on next generation 

sequencing in clinical and public health 

laboratories and laboratory data 

exchange and harmonization. Agenda 

items are subject to change as priorities 

dictate. 

It is the policy of CLIAC to accept 

written public comments and provide a 

brief period for oral public comments 

pertinent to agenda items. Public 

comment periods for each agenda item 

are scheduled immediately prior to the 

Committee discussion period for that 

item. In general, each individual or 

group requesting to present an oral 

comment will be limited to a total time 

of five minutes (unless otherwise 

indicated). Speakers should email 

CLIAC@cdc.gov or notify the contact 

person at least five business days prior 

to the meeting date. For individuals or 

groups unable to attend the meeting, 

CLIAC accepts written comments until 

the date of the meeting (unless 

otherwise stated). However, it is 

requested that comments be submitted 

at least five business days prior to the 

meeting date so that the comments may 

be made available to the Committee for 

their consideration and public 

distribution. All written comments will 

be included in the meeting Summary 

Report posted on the CLIAC website. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2021–20151 Filed 9–16–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–21–1274; Docket No. CDC–2021– 

0096] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other Federal 

agencies the opportunity to comment on 

a proposed and/or continuing 

information collection, as required by 

the Paperwork Reduction Act of 1995. 

This notice invites comment on the 

Million Hearts Hospital & Health 

System Recognition Program. This 

program recognizes institutions working 

systematically to improve the 

cardiovascular health of the population 

and communities they serve. 

DATES: CDC must receive written 

comments on or before November 16, 

2021. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2021– 

0096 by any of the following methods: 

• Federal eRulemaking Portal: 

Regulations.gov. Follow the instructions 

for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600